1154703-35-1

Basic information

• Product Name: 3-(2-t-butoxycarbonylaminophenyl)propionic acid 2-(11,17-dihydroxy-10,13-dimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-oxo-ethyl ester
• Synonyms: 3-(2-t-butoxycarbonylaminophenyl)propionic acid 2-(11,17-dihydroxy-10,13-dimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-oxo-ethyl ester
• CAS NO: 1154703-35-1
• Molecular Weight: 609.76
• Mol File: 1154703-35-1.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 3-(2-t-butoxycarbonylaminophenyl)propionic acid 2-(11,17-dihydroxy-10,13-dimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-oxo-ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(2-t-butoxycarbonylaminophenyl)propionic acid 2-(11,17-dihydroxy-10,13-dimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-oxo-ethyl ester(1154703-35-1)
• EPA Substance Registry System: 3-(2-t-butoxycarbonylaminophenyl)propionic acid 2-(11,17-dihydroxy-10,13-dimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-oxo-ethyl ester(1154703-35-1)

Safety Data

• Hazardous Substances Data: 1154703-35-1(Hazardous Substances Data)

Upstream product

• 50-23-7 HYDROCORTISONE 
• 1070955-54-2 C₁₄H₁₉NO₄ 

Downstream Products

• 553-03-7 3,4-dihydro-2(1H)-quinolone 
• 50-23-7 HYDROCORTISONE 

Relevant articles and documents

Design, synthesis, and pharmacological effects of a cyclization-activated steroid prodrug for colon targeting in inflammatory bowel disease

Glucocorticoids are used in the treatment of inflammatory bowel disease. A limitation to their use is that they undergo absorption from the GIT before reaching the colon causing severe systemic side effects. We report here on a novel prodrug approach to targeting corticosteroids to the colon. The design involves attaching a 21-ester group that suppresses absorption during transit to the colon. The prodrug is designed to be primed by colonic microflora liberating an amino ester that cyclizes releasing the steroid. One of the prodrugs 5b was as efficacious as prednisolone in the murine DSS model but did not cause thymic atrophy, a marker for systemic steroid effects.